Adaptive Biotechnologies

Commercial-stage biotechnology company whose clonoSEQ NGS assay is widely used for measurable residual disease assessment in hematologic malignancies.

Back to company catalog

Hematologic Malignancies · Immune-receptor NGS / MRD · Commercial

Compare report options